{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:16:37Z","timestamp":1791288997996,"version":"4.3.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lysosomal storage disorders (LSD) are rare diseases, caused by inherited deficiencies of lysosomal enzymes\/transporters, that affect 1 in 7000 to 1 in 8000 newborns. Individuals with LSDs face long diagnostic journeys during which debilitating and life-threatening events can occur. Clinical trials and classical descriptions of LSDs typically focus on common manifestations, which are not representative of the vast phenotypic heterogeneity encountered in real-world experience. Additionally, recognizing that there was a limited understanding of the natural history, disease progression, and real-world clinical outcomes of rare LSDs, a collaborative partnership was pioneered 30\u00a0years ago to address these gaps. The Rare Disease Registries (RDR) (for Gaucher, Fabry, Mucopolysaccharidosis type I, and Pompe), represent the largest observational database for these LSDs. Over the past thirty years, data from the RDRs have helped to inform scientific understanding and the development of comprehensive monitoring and treatment guidelines by creating a framework for data collection and establishing a standard of care, with an overarching goal to improve the quality of life of affected patients. Here, we highlight the history, process, and impact of the RDRs, and discuss the lessons learned and future directions.<\/jats:p>","DOI":"10.1186\/s13023-022-02517-0","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T23:02:21Z","timestamp":1665961341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rare lysosomal disease registries: lessons learned over three decades of real-world evidence"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-6421","authenticated-orcid":false,"given":"P. K.","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"1","key":"2517_CR1","first-page":"87","volume":"26","author":"S Bruni","year":"2007","unstructured":"Bruni S, Loschi L, Incerti C, Gabrielli O, Coppa GV. Update on treatment of lysosomal storage diseases. Acta Myol. 2007;26(1):87\u201392.","journal-title":"Acta Myol"},{"issue":"24","key":"2517_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","volume":"6","author":"A Sun","year":"2018","unstructured":"Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2517_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","volume":"31","author":"G Parenti","year":"2013","unstructured":"Parenti G, Pignata C, Vajro P, Salerno M. New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med. 2013;31(1):11\u201320.","journal-title":"Int J Mol Med"},{"issue":"12","key":"2517_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","volume":"18","author":"SR Bonam","year":"2019","unstructured":"Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019;18(12):923\u201348.","journal-title":"Nat Rev Drug Discov"},{"key":"2517_CR5","unstructured":"Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis Copyright \u00a9 2006, Oxford PharmaGenesis\u2122. 2006."},{"issue":"2\u20133","key":"2517_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10545-006-0246-7","volume":"29","author":"JM Fletcher","year":"2006","unstructured":"Fletcher JM. Screening for lysosomal storage disorders\u2013a clinical perspective. J Inherit Metab Dis. 2006;29(2\u20133):405\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"2517_CR7","doi-asserted-by":"publisher","first-page":"100199","DOI":"10.1016\/j.jlr.2022.100199","volume":"63","author":"LT Lelieveld","year":"2022","unstructured":"Lelieveld LT, Gerhardt S, Maas S, Zwiers KC, de Wit C, Beijk EH, et al. Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish. J Lipid Res. 2022;63:100199.","journal-title":"J Lipid Res"},{"key":"2517_CR8","doi-asserted-by":"publisher","first-page":"100544","DOI":"10.1016\/j.ymgmr.2019.100544","volume":"21","author":"L d'Avila Paskulin","year":"2019","unstructured":"d\u2019Avila Paskulin L, Starosta RT, Zizemer VS, Basgalupp S, Bertholdo D, Vairo FPe, et al. Rare GBA1 genotype associated with severe bone disease in Gaucher disease type 1. Mol Genet Metab Rep. 2019;21:100544.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2517_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13023-020-01519-0","volume":"15","author":"CEM Hollak","year":"2020","unstructured":"Hollak CEM, Sirrs S, van den Berg S, van der Wel V, Langeveld M, Dekker H, et al. Registries for orphan drugs: generating evidence or marketing tools? Orphanet J Rare Dis. 2020;15(1):235.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"2517_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324(21):1464\u201370.","journal-title":"N Engl J Med"},{"key":"2517_CR11","first-page":"177","volume":"95","author":"RE Lee","year":"1982","unstructured":"Lee RE. The pathology of Gaucher disease. Prog Clin Biol Res. 1982;95:177\u2013217.","journal-title":"Prog Clin Biol Res"},{"issue":"6","key":"2517_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","volume":"71","author":"A Zimran","year":"1992","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine. 1992;71(6):337\u201353 (Baltimore).","journal-title":"Medicine"},{"issue":"8","key":"2517_CR13","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/jbmr.1680","volume":"27","author":"A Khan","year":"2012","unstructured":"Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the international collaborative Gaucher group (ICGG) Gaucher registry. J Bone Miner Res. 2012;27(8):1839\u201348.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2517_CR14","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1002\/ajh.24055","volume":"90","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Understanding the natural history of Gaucher disease. Am J Hematol. 2015;90(Suppl 1):S6-11.","journal-title":"Am J Hematol"},{"key":"2517_CR15","unstructured":"Patient-Centered Outcomes Research Institute (PCORI). Patient Engagement Is Critical to Producing Useful, Relevant Research 2019 [Available from: https:\/\/www.pcori.org\/blog\/patient-engagement-critical-producing-useful-relevant-research] Accessed May 2022"},{"key":"2517_CR16","first-page":"107338","volume":"59","author":"A Nowak","year":"2021","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2021;59:107338.","journal-title":"J Med Genet"},{"issue":"11","key":"2517_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91(11):1082\u20139.","journal-title":"Am J Hematol"},{"issue":"3","key":"2517_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1042\/EBC20190090","volume":"64","author":"M van Eijk","year":"2020","unstructured":"van Eijk M, Ferraz MJ, Boot RG, Aerts J. Lyso-glycosphingolipids: presence and consequences. Essays Biochem. 2020;64(3):565\u201378.","journal-title":"Essays Biochem"},{"issue":"1","key":"2517_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2517_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1524-4733.2003.65309.x","volume":"6","author":"C Acquadro","year":"2003","unstructured":"Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient\u2019s perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration, February 16, 2001. Value Health. 2003;6(5):522\u201331.","journal-title":"Value Health"},{"issue":"1","key":"2517_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","volume":"46","author":"B Rosenbloom","year":"2011","unstructured":"Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, et al. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher registry. Blood Cells Mol Dis. 2011;46(1):95\u2013102.","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2517_CR22","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","volume":"105","author":"BE Rosenbloom","year":"2005","unstructured":"Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher registry. Blood. 2005;105(12):4569\u201372.","journal-title":"Blood"},{"issue":"1","key":"2517_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46(1):66\u201372.","journal-title":"Blood Cells Mol Dis"},{"key":"2517_CR24","volume-title":"The online metabolic and molecular bases of inherited disease","author":"GA Grabowski","year":"2019","unstructured":"Grabowski GA, Kolodny EH, Weinreb NJ, Rosenbloom BE, Prakash-Cheng A, Kaplan P, et al. Gaucher disease: phenotypic and genetic variation. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors., et al., The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Education; 2019."},{"issue":"9","key":"2517_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84(9):880\u20137.","journal-title":"Neurology"},{"issue":"2","key":"2517_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","volume":"33","author":"G Bultron","year":"2010","unstructured":"Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson\u2019s disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33(2):167\u201373.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"2517_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","volume":"11","author":"E Sidransky","year":"2012","unstructured":"Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986\u201398.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2517_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative Gaucher group neurological outcomes subregistry. J Inher Metab Dis. 2010;33(4):339\u201346.","journal-title":"J Inher Metab Dis"},{"issue":"9","key":"2517_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol. 2011;57(9):1093\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2517_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9(1):34\u201345.","journal-title":"Genet Med"},{"issue":"1","key":"2517_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"2517_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2008;93(2):112\u201328.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2517_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N. Gaucher disease type 1 patients from the ICGG Gaucher registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132(2):100\u201311.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2517_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","volume":"119","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry registry. Mol Genet Metab. 2016;119(1\u20132):151\u20139.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2517_CR35","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","volume":"267","author":"DW Stockton","year":"2020","unstructured":"Stockton DW, Kishnani P, van der Ploeg A, Llerena J Jr, Boentert M, Roberts M, et al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267(10):3038\u201353.","journal-title":"J Neurol"},{"issue":"7","key":"2517_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/archdischild-2020-319040","volume":"106","author":"R Giugliani","year":"2021","unstructured":"Giugliani R, Muschol N, Keenan HA, Dant M, Muenzer J. Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I. Arch Dis Child. 2021;106(7):674\u20139.","journal-title":"Arch Dis Child"},{"issue":"4","key":"2517_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147(4):561\u201370.","journal-title":"Br J Haematol"},{"key":"2517_CR38","unstructured":"Burwell SM. 2015. [Available from: https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/advisory-committees\/heritable-disorders\/reports-recommendations\/secretary-final-response-pompe.pdf] Accessed February 2022."},{"issue":"12","key":"2517_CR39","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/CJN.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol. 2010;5(12):2220\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2517_CR40","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1002\/ajmg.a.61378","volume":"179","author":"D Viskochil","year":"2019","unstructured":"Viskochil D, Clarke LA, Bay L, Keenan H, Muenzer J, Guffon N. Growth patterns for untreated individuals with MPS I: report from the international MPS I registry. Am J Med Genet A. 2019;179(12):2425\u201332.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2517_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s13063-017-2287-7","volume":"18","author":"A Rath","year":"2017","unstructured":"Rath A, Salamon V, Peixoto S, Hivert V, Laville M, Segrestin B, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18(1):556.","journal-title":"Trials"},{"issue":"11","key":"2517_CR42","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","volume":"40","author":"AJJ Reuser","year":"2019","unstructured":"Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J Jr, Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1079 patients with Pompe disease: data from the Pompe registry. Hum Mutat. 2019;40(11):2146\u201364.","journal-title":"Hum Mutat"},{"issue":"2","key":"2517_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009;11(2):92\u2013100.","journal-title":"Genet Med"},{"key":"2517_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-6-61","volume":"6","author":"JA Cole","year":"2011","unstructured":"Cole JA, Taylor JS, Hangartner TN, Weinreb NJ, Mistry PK, Khan A. Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis. 2011;6:61.","journal-title":"Orphanet J Rare Dis"},{"key":"2517_CR45","unstructured":"Cappellini MD, Rosenbloom B, Dragosky M, Weinreb N, McClain M, Sedulic D, et al. Hematologic malignancies and gammopathies in Gaucher disease type 1. Abstract EP1044. European Haematology Association. 2020."},{"issue":"10","key":"2517_CR46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I registry. Genet Med. 2014;16(10):759\u201365.","journal-title":"Genet Med"},{"issue":"1","key":"2517_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","volume":"103","author":"BJ Byrne","year":"2011","unstructured":"Byrne BJ, Kishnani PS, Case LE, Merlini L, Muller-Felber W, Prasad S, et al. Pompe disease: design, methodology, and early findings from the Pompe registry. Mol Genet Metab. 2011;103(1):1\u201311.","journal-title":"Mol Genet Metab"},{"issue":"18","key":"2517_CR48","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160(18):2835\u201343.","journal-title":"Arch Intern Med"},{"issue":"2","key":"2517_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inher Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inher Metab Dis"},{"issue":"5","key":"2517_CR50","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23(5):1600\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2517_CR51","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/gim.2013.53","volume":"15","author":"DP Germain","year":"2013","unstructured":"Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry. Genet Med. 2013;15(12):958\u201365.","journal-title":"Genet Med"},{"issue":"10","key":"2517_CR52","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","volume":"161A","author":"PS Kishnani","year":"2013","unstructured":"Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J, et al. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A. 2013;161A(10):2431\u201343.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2517_CR53","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2517_CR54","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1542\/peds.2007-2144","volume":"122","author":"H Andersson","year":"2008","unstructured":"Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122(6):1182\u201390.","journal-title":"Pediatrics"},{"issue":"5","key":"2517_CR55","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"issue":"3","key":"2517_CR56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ehf2.12647","volume":"7","author":"C Wanner","year":"2020","unstructured":"Wanner C, Feldt-Rasmussen U, Jovanovic A, Linhart A, Yang M, Ponce E, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail. 2020;7(3):825\u201334.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2517_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13023-020-01656-6","volume":"16","author":"P Deegan","year":"2021","unstructured":"Deegan P, Khan A, Camelo JS Jr, Batista JL, Weinreb N. The international collaborative Gaucher group GRAF (Gaucher risk assessment for fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. Orphanet J Rare Dis. 2021;16(1):92.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2517_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","volume":"53","author":"A Ortiz","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry registry. J Med Genet. 2016;53(7):495\u2013502.","journal-title":"J Med Genet"},{"key":"2517_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckv169.006","author":"M Zaletel","year":"2015","unstructured":"Zaletel M, Kralj M, Magajne M, Doupi P. Methodological guidelines and recommendations for efficient and rationale governance of patient registries: Metka Zalatel. Eur J Public Health. 2015. https:\/\/doi.org\/10.1093\/eurpub\/ckv169.006.","journal-title":"Eur J Public Health"},{"issue":"1","key":"2517_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13023-019-1139-9","volume":"14","author":"MI Bellgard","year":"2019","unstructured":"Bellgard MI, Snelling T, McGree JM. RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework. Orphanet J Rare Dis. 2019;14(1):176.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"2517_CR61","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","volume":"140","author":"DF Kronn","year":"2017","unstructured":"Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, et al. Management of confirmed newborn-screened patients With Pompe disease across the disease spectrum. Pediatrics. 2017;140(Suppl 1):S24-s45.","journal-title":"Pediatrics"},{"key":"2517_CR62","unstructured":"U.S. Food and Drug Administration. Real-World Evidence [Available from: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence] Accessed February 2022."},{"key":"2517_CR63","unstructured":"European Medicines Agency (EMA). Patient Registries [Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/patient-registries] Accessed February 2022."},{"key":"2517_CR64","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/978-3-319-67144-4_34","volume":"1031","author":"SC Groft","year":"2017","unstructured":"Groft SC, de la Paz Posada M. Preparing for the future of rare diseases. Adv Exp Med Biol. 2017;1031:641\u20138.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"2517_CR65","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-019-1182-6","volume":"14","author":"A Donald","year":"2019","unstructured":"Donald A, Cizer H, Finnegan N, Collin-Histed T, Hughes DA, Davies EH. Measuring disease activity and patient experience remotely using wearable technology and a mobile phone app: outcomes from a pilot study in Gaucher disease. Orphanet J Rare Dis. 2019;14(1):212.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T23:28:02Z","timestamp":1701214082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02517-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent to participate in the Registries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PKM has received research and travel support from Sanofi. PK has received research\/grant support from Sanofi and Amicus Therapeutics, has received consulting fees and honoraria from Sanofi, Amicus Therapeutics, Maze Therapeutics, JCR Pharmaceutical and Asklepios Biopharmaceutical, Inc. (AskBio), is a member of the Pompe and Gaucher Disease Registry Advisory Board for Sanofi, Amicus Therapeutics, and Baebies, and has equity in Asklepios Biopharmaceutical, Inc. (AskBio), which is developing gene therapy for Pompe disease and Maze Therapeutics, which is developing a small molecule in Pompe disease. CW has received honoraria for board meetings and lecturing from Amicus, Chiesi, Idorsia, Sanofi, and Takeda. JB, JLB, DD, JF are employees of Sanofi and may hold Sanofi stocks.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}